Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Peter Kraft, Ph.D.

Co-Author

This page shows the publications co-authored by Peter Kraft and Lorelei Mucci.
Connection Strength

2.342
  1. Sniffing out significant "Pee values": genome wide association study of asparagus anosmia. BMJ. 2016 Dec 13; 355:i6071.
    View in: PubMed
    Score: 0.179
  2. Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes. Cancer Epidemiol Biomarkers Prev. 2016 05; 25(5):745-9.
    View in: PubMed
    Score: 0.169
  3. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA. 2016 Jan 05; 315(1):68-76.
    View in: PubMed
    Score: 0.168
  4. Circadian clock genes and risk of fatal prostate cancer. Cancer Causes Control. 2015 Jan; 26(1):25-33.
    View in: PubMed
    Score: 0.155
  5. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2027-31.
    View in: PubMed
    Score: 0.150
  6. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014 Jun; 65(6):1069-75.
    View in: PubMed
    Score: 0.146
  7. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate. 2012 Feb 01; 72(2):209-16.
    View in: PubMed
    Score: 0.121
  8. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6.
    View in: PubMed
    Score: 0.121
  9. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer. 2009 Jun 01; 124(11):2683-9.
    View in: PubMed
    Score: 0.106
  10. Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2009 Jun; 18(6):1859-63.
    View in: PubMed
    Score: 0.106
  11. Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. J Natl Cancer Inst. 2021 Apr 01.
    View in: PubMed
    Score: 0.060
  12. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 Mar; 53(3):413.
    View in: PubMed
    Score: 0.060
  13. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 01; 53(1):65-75.
    View in: PubMed
    Score: 0.059
  14. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2019 02; 51(2):363.
    View in: PubMed
    Score: 0.052
  15. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431.
    View in: PubMed
    Score: 0.052
  16. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2019 01 17; 10(1):382.
    View in: PubMed
    Score: 0.052
  17. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2018 11 05; 9(1):4616.
    View in: PubMed
    Score: 0.051
  18. Precision Prevention and Early Detection of Cancer: Fundamental Principles. Cancer Discov. 2018 07; 8(7):803-811.
    View in: PubMed
    Score: 0.050
  19. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018 07; 50(7):928-936.
    View in: PubMed
    Score: 0.050
  20. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018 06 11; 9(1):2256.
    View in: PubMed
    Score: 0.050
  21. Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia. Int J Cancer. 2017 11 01; 141(9):1794-1802.
    View in: PubMed
    Score: 0.047
  22. ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). Prostate. 2015 Nov; 75(15):1677-81.
    View in: PubMed
    Score: 0.041
  23. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer. 2015 Jun 15; 121(12):1949-56.
    View in: PubMed
    Score: 0.040
  24. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):255-60.
    View in: PubMed
    Score: 0.039
  25. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014 Oct; 46(10):1103-9.
    View in: PubMed
    Score: 0.038
  26. Common genetic variation of the calcium-sensing receptor and lethal prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):118-26.
    View in: PubMed
    Score: 0.034
  27. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012 May 02; 104(9):690-9.
    View in: PubMed
    Score: 0.032
  28. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis. 2011 Jun; 32(6):853-9.
    View in: PubMed
    Score: 0.030
  29. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2869-76.
    View in: PubMed
    Score: 0.029
  30. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010 Aug 01; 19(15):3089-101.
    View in: PubMed
    Score: 0.028
  31. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila). 2010 May; 3(5):604-10.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.